ATE286125T1 - Regulation der genexpression von bcl-2 - Google Patents

Regulation der genexpression von bcl-2

Info

Publication number
ATE286125T1
ATE286125T1 AT94929298T AT94929298T ATE286125T1 AT E286125 T1 ATE286125 T1 AT E286125T1 AT 94929298 T AT94929298 T AT 94929298T AT 94929298 T AT94929298 T AT 94929298T AT E286125 T1 ATE286125 T1 AT E286125T1
Authority
AT
Austria
Prior art keywords
bcl
regulation
gene expression
gene
growth
Prior art date
Application number
AT94929298T
Other languages
English (en)
Inventor
John C Reed
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE286125T1 publication Critical patent/ATE286125T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT94929298T 1993-09-20 1994-09-20 Regulation der genexpression von bcl-2 ATE286125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12425693A 1993-09-20 1993-09-20
PCT/US1994/010725 WO1995008350A1 (en) 1993-09-20 1994-09-20 REGULATION OF bcl-2 GENE EXPRESSION

Publications (1)

Publication Number Publication Date
ATE286125T1 true ATE286125T1 (de) 2005-01-15

Family

ID=22413765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929298T ATE286125T1 (de) 1993-09-20 1994-09-20 Regulation der genexpression von bcl-2

Country Status (9)

Country Link
EP (2) EP1584682B1 (de)
JP (6) JP2001505401A (de)
AT (1) ATE286125T1 (de)
CA (1) CA2172153C (de)
DE (2) DE69435218D1 (de)
DK (1) DK1584682T3 (de)
ES (1) ES2326118T3 (de)
PT (1) PT1584682E (de)
WO (1) WO1995008350A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP0941124A4 (de) * 1996-11-21 2004-12-15 Univ Nebraska Antisense-oligonukleotid zusammenstellungen zur gezielten tötung von krebszellen
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
EP1093373A4 (de) * 1998-07-02 2005-04-13 Univ Columbia OLIGONUKLEOTIDE INHIBITOREN DES bcl-xl
PT1104306E (pt) * 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
GB9910119D0 (en) * 1999-04-30 1999-06-30 Novartis Ag Organic compounds
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2004106511A1 (ja) 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
PL1957044T3 (pl) 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
ES2548240T3 (es) * 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
CA2890725A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
US12428641B2 (en) 2017-09-15 2025-09-30 Commonwealth Scientific And Industrial Research Organisation RNA molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
EP0590090A4 (de) * 1991-06-18 1995-04-12 Univ Temple Selektive hemmung leukämischer zellproliferation durch -i(bcr-abl) antisens-oligonukleotide.
WO1993020200A1 (en) * 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Modified cells and method of treatment

Also Published As

Publication number Publication date
JP2006182651A (ja) 2006-07-13
JP2009029812A (ja) 2009-02-12
EP1584682A1 (de) 2005-10-12
CA2172153C (en) 2010-03-09
EP0722342A1 (de) 1996-07-24
JP2003026609A (ja) 2003-01-29
ES2326118T3 (es) 2009-10-01
DE69434209D1 (de) 2005-02-03
DE69435218D1 (de) 2009-08-27
EP1584682B1 (de) 2009-07-15
WO1995008350A1 (en) 1995-03-30
EP0722342A4 (de) 1999-01-07
JP2001505401A (ja) 2001-04-24
PT1584682E (pt) 2009-08-03
CA2172153A1 (en) 1995-03-30
EP0722342B1 (de) 2004-12-29
JP2010184933A (ja) 2010-08-26
JP2006257092A (ja) 2006-09-28
DK1584682T3 (da) 2009-09-21
JP4057848B2 (ja) 2008-03-05

Similar Documents

Publication Publication Date Title
DE69435218D1 (de) Regulation der Genexpression von bcl-2
ATE189475T1 (de) Wachstums-differenzierungsfaktor der tgf-b familie
DE69128893D1 (de) Genetische veränderung von endothelzellen
ATE215125T1 (de) ßHEAT SHOCKß-PROTEINE UND BEHANDLUNG VON TUMOREN
ATE184882T1 (de) Materialien und methoden zur schädlingsbekämpfung
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
EP0948522A4 (de) Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren
DE69227392D1 (de) Serumfreies Medium zur Züchtung von Tierzellen
AU658296B2 (en) 7 beta-substituted-4-aza-5 alpha-cholestan-3-ones as 5 alpha-reductase inhibitors
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE3767470D1 (de) System zum regeln der von mehreren kathoden einer ionenquelle ausgehenden stroeme und ionenantrieb.
FI962693L (fi) Geeni-ilmentymisen kontrolli
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69405546D1 (de) Lineare mikrowellenquelle zur plasmabehandlung von flächen.
EP0585464A4 (de) Stark wasserabdorbierender reis, verfahren zur dessen herstellung und verwendung.
DE69033756D1 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
DE69016693D1 (de) Züchtung von transformierten Mikroorganismen.
PT733370E (pt) Utilizacao da sequencia de um promotor genico para o tratamento de doencas reumaticas
DE69316908D1 (de) Polderprinzip und -verfahren unter verwendung von schutzwänden
DE59307112D1 (de) Verwendung von Polyorganosiloxan-Pfropfprodukten zur Lederzurichtung
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
FI883135A0 (fi) Homocyklostatin och cyklostatin innehaollande polypeptider som antihypertensiva medel.
DK189285D0 (da) (6,11-dihydro-11-oxodibenz(b,e)oxepinyl)-pentancarboxylsyrer, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties